Teva Canada

Teva Canada in the Federal Court’s strike of judicial review by Novo Nordisk Canada Inc.


Teva Canada




Intellectual Property

Date Closed


Pharmaceuticals and Life Sciences

Lead Office



In 2019-2020 Osler successfully represented Teva Canada in a judicial review application brought by Novo Nordisk Canada Inc. in respect of a decision of the Minister of Health concerning Teva’s drug submission for liraglutide. The application was struck, providing a major victory for the generic industry as Teva resisted brand interference in review of its drug submission.

Teva Canada is a pharmaceutical company specializing in developing and producing generic medicines with a portfolio of 3,500 products in each therapeutic area.

Osler, Hoskin & Harcourt LLP advised Teva Canada with a team consisting of Brad White, Nathaniel Lipkus, Faylene Lunn and Lillian Wallace (Intellectual Property).